Addiction

Papers
(The H4-Index of Addiction is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Issue Information209
Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling180
An Addiction series on regional perspectives on addiction‐related problems179
Society for the Study of Addiction Annual Conference 2024122
94
92
Education matters: longitudinal pathways to mid‐life heavy drinking in a national cohort of black Americans88
Impulsivity behaviors and white matter mediate the relationship between genetic risk for cannabis use disorder and early cannabis use in adolescents86
Will Australia's tightened prescription system reduce nicotine vaping among young people?86
Commentary on Nower et al: The Pathways Model should apply to non‐clinical gambling patterns80
Significant changes in preference of illicit drug use in a population of Hanoi, Vietnam—A 6‐year wastewater study (2018–2023)80
Commentary on Keyes and Patrick: Changes in psychedelic use in the United States may require changes in our narrative of psychedelic harms80
National profile on substance use, substance use‐related problems and policy: The case of Chile74
Structure and stability of internet gaming disorder from childhood to late adolescence: A 5‐wave birth cohort study70
68
Estimating recent trends in alcohol sales in the United Kingdom from alcohol duty revenue67
Systematic review and meta‐analyses of cytisine to support tobacco cessation66
Does recreational cannabis legalization change cannabis use patterns? Evidence from secondary school students in Uruguay66
Rare but relevant series57
Cannabis: Global Histories by Lucas Richert and James H. Mills, editors56
How substance use prevention research gets used in United States federal policy55
Naloxone administration—no balance without titration52
Response to Hall et al.: Prescription psychostimulants for amphetamine‐type stimulant use disorder ‐ acknowledging challenges but not giving up on its potential cost‐effectiveness50
Commentary on Stull et al.: Considering person‐specific heterogeneity when modeling time‐varying trends49
Cost‐effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO‐HCV trial47
Quantifying alcohol‐attributable disability‐adjusted life years to others than the drinker in Aotearoa/New Zealand: A modelling study based on administrative data47
Did the under‐reporting of meth/amphetamine use increase in a general population survey in Australia as negative media coverage increased?45
Assessing the impacts of alcohol outlets on crime as a natural experiment: agglomeration, churning and spatial effects44
Nicotine strength of e‐liquids used by adult vapers in Great Britain: A population survey 2016 to 202442
Predictors of substance use during treatment for addiction: A network analysis of ecological momentary assessment data42
Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data40
Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial37
Chronic obstructive pulmonary disease in heroin users: An underappreciated issue with clinical ramifications35
Risk of readmission among individuals with cannabis use disorder during a 15‐year cohort study: the impact of socio‐economic factors and psychiatric comorbidity35
Age, period and cohort effects of heavy episodic drinking by sex/gender and socioeconomic position in Canada, 2000–202134
Austin Bradford Hill’s ‘Environment and disease: Association or causation’34
0.093415021896362